Design, Synthesis, Biological Evaluation, Molecular Dynamics, and ADME‐T Investigation of Pyrrol‐4,5‐Dihydro‐1H‐Pyrazol‐Pyridine Derivatives as PARP1 Inhibitors as Anticancer Agents
ChemistrySelect · 2026-11 · 11 (43)
DOI: 10.1002/slct.75070 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 16.11.2026. Verfasst von Harshwardhan Singh und 8 weiteren Autor:innen. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Indian Council of Medical Research.
Abstract (Originalsprache)
Poly (ADP‐ribose) polymerase 1 (PARP1) is a central regulator of DNA repair, genome stability, transcription, and cell survival, and its dysregulation has emerged as a potential target for cancer therapy. In this study, we designed and synthesized a series of eight pyrrolyl‐pyrazolinyl‐pyridine derivatives (3a–h) using a bioisosteric strategy in which the pyridine ring was incorporated to emulate the nicotinamide pharmacophore and engage the catalytic pocket of PARP1. The synthesized compounds were evaluated for their antiproliferative activity against A549, MCF‐7, MDA‐MB‐468, and A375 cancer cell lines. Among the series, compound 3d demonstrated the most balanced biological profile, inhibiting A549 and MDA‐MB‐468 cells by 51.78% and 23.10%, respectively, at 20 µM, and exhibiting PARP1 inhibitory activity with an IC 50 of 11.60 µM, as compared to 3‐Aminobbenzamide with IC 50 of 1.45 µM. Mechanistically, 3d induced S‐phase alteration in A549 cells, consistent with replication stress‐associated cell‐cycle disruption. Molecular docking showed favorable accommodation within the PARP1 active site, with 3d achieving the good binding score of −8.516 kcal/mol, in comparison with Rucaparib with −8.482 kcal/mol, while molecular dynamics simulations supported the stability of the ligand‐protein complex. Collectively, these findings identify 3d as a lead scaffold for further optimization toward PARP1‐targeted anticancer drug development.
Förderung
- Indian Council of Medical Research
Zitieren
APA
Singh, H., Singh, A. K., Kumar, A., Prajapati, V., Verma, A., Singh, S. K., Navik, U., Uttam, V., & Kumar, P. (2026). Design, Synthesis, Biological Evaluation, Molecular Dynamics, and ADME‐T Investigation of Pyrrol‐4,5‐Dihydro‐1H‐Pyrazol‐Pyridine Derivatives as PARP1 Inhibitors as Anticancer Agents. ChemistrySelect, 11(43). https://doi.org/10.1002/slct.75070
Vancouver
Singh H, Singh AK, Kumar A, Prajapati V, Verma A, Singh SK, et al. Design, Synthesis, Biological Evaluation, Molecular Dynamics, and ADME‐T Investigation of Pyrrol‐4,5‐Dihydro‐1H‐Pyrazol‐Pyridine Derivatives as PARP1 Inhibitors as Anticancer Agents. ChemistrySelect. 2026;11(43). doi:10.1002/slct.75070
BibTeX
@article{Singh2026,
author = {Singh, Harshwardhan and Singh, Ankit Kumar and Kumar, Adarsh and Prajapati, Vineet and Verma, Amita and Singh, Sumeet Kumar and Navik, Umashanker and Uttam, Vivek and Kumar, Pradeep},
title = {Design, Synthesis, Biological Evaluation, Molecular Dynamics, and ADME‐T Investigation of Pyrrol‐4,5‐Dihydro‐1H‐Pyrazol‐Pyridine Derivatives as PARP1 Inhibitors as Anticancer Agents},
journal = {ChemistrySelect},
year = {2026},
volume = {11},
number = {43},
doi = {10.1002/slct.75070}
}
EUVIMED